A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 10, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development ...

The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response ...

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial ...

Each year, over 1.2 million Americans receive a cancer diagnosis, a journey that can be both overwhelming and daunting.

As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and ...